Dupuytren’s Disease (Palmar Fibromatosis) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 

Dupuytren's disease, also known as Palmar fibromatosis, is characterized by the gradual thickening and contraction of the palmar fascia, a layer of tissue beneath the skin and above the tendons, nerves, blood vessels, and bones in the palm and fingers. This fibrous layer stabilizes the skin on the palm side of the hand, preventing excessive mobility. However, in individuals with Dupuytren's, the fascia thickens over time, resulting in a tightening or shortening effect. Typically, the initial indication of Dupuytren's is the formation of nodules, or lumps of tissue, beneath the skin in the palm. As the condition progresses slowly over the years, these nodules may evolve into cords, leading to contractures. Signs and symptoms of Dupuytren's include nodules, cords, and contractures. Dupuytren's disease is not life-threatening and does not metastasize to vital organs. A benign proliferation of myofibroblasts and fibroblasts characterizes it. While the exact cause remains unclear, several factors, such as repetitive trauma, smoking, alcohol addiction, frozen shoulder, epilepsy, and long-term phenobarbital usage, have been associated with its development. The disease progresses through various stages, beginning with the proliferative phase marked by increased fibroblastic activity and cellular proliferation. This is followed by the active phase, where nodule formation occurs. Conservative treatment methods are typically preferred before considering surgical intervention for plantar fibromatosis, another condition linked to similar factors. Although there is no cure for Dupuytren's disease, surgical procedures like full fasciectomy can help alleviate symptoms, with lower recurrence rates compared to local and wide excisions.

Thelansis’s “Dupuytren’s Disease (Palmar Fibromatosis) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Dupuytren’s Disease (Palmar Fibromatosis) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Dupuytren’s Disease (Palmar Fibromatosis) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Dupuytren’s Disease (Palmar Fibromatosis) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Dupuytren’s Disease (Palmar Fibromatosis) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033